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Abstract
Recently there has been a considerable rise in the frequency of metabolic diseases, such as obesity, due to changes in lifestyle and resultant
imbalances between energy intake and expenditure. Whey proteins are considered as potentially important components of a dietary solution
to the obesity problem. However, the roles of individual whey proteins in energy balance remain poorly understood. This study investigated
the effects of a high-fat diet (HFD) containing α-lactalbumin (LAB), a specific whey protein, or the non-whey protein casein (CAS), on energy
balance, nutrient transporters expression and enteric microbial populations. C57BL/6J mice (n 8) were given an HFD containing either 20%
CAS or LAB as protein sources or a low-fat diet containing CAS for 10 weeks. HFD-LAB-fed mice showed a significant increase in cumulative
energy intake (P= 0·043), without differences in body weight, energy expenditure, locomotor activity, RER or subcutaneous and epididymal
white adipose tissue weight. HFD-LAB intake led to a decrease in the expression of glut2 in the ileum (P= 0·05) and in the fatty acid
transporter cd36 (P< 0·001) in both ileum and jejunum. This suggests a reduction in absorption efficiency within the small intestine in the
HFD-LAB group. DNA from faecal samples was used for 16S rRNA-based assessment of intestinal microbiota populations; the genera
Lactobacillus, Parabacteroides and Bifidobacterium were present in significantly higher proportions in the HFD-LAB group. These data
indicate a possible functional relationship between gut microbiota, intestinal nutrient transporters and energy balance, with no impact on
weight gain.
Key words: Dietary α-lactalbumin: Energy balance: Gut microbiota: Nutrient transporter expression: Whey proteins: High-fat diet
Obesity has emerged as one of the most prevalent global health
problems over the last 30 years because of its association with
comorbidities such as chronic inflammations, type 2 diabetes,
cardiovascular disorders and certain types of cancer(1). Whilst
the aetiology of obesity is multifactorial, there is a growing
recognition that high energy density diets (containing high
levels of fat and sugar) are major contributors to long-term
imbalance between energy intake and energy expenditure(2),
with comparable effects seen in rodents including mice such as
the C57BL/6J strain. Indeed, energy-dense diets increase
intestinal energy absorption and fat storage in adipose tissue(3).
In addition, these diets impair the hypothalamic regulation of
hormones involved in the control of energy balance(4). Thus,
one approach to reducing weight gain or causing weight loss
would be to devise interventions that affect the cross-talk
between the gut, adipose tissue and the hypothalamic
mechanisms regulating energy balance.
Nutrient digestion and absorption provides the necessary
energy for the survival of living organisms, and the gastro-
intestinal tract has evolved to optimise these processes(5). In
particular, nutrient absorption takes place in the duodenum,
jejunum and ileum, through paracellular movements or by
uptake through specific nutrient transporters, which are able to
transport fats (e.g. fatty acid transporter protein 4 (FATP4);
cluster differentiation 36 (CD36)), sugars (i.e. GLUT2;
sodium-glucose transporter protein 1 (SGLT1)) and amino acids
Abbreviations: CAS, casein; CD36, cluster differentiation 36; eWAT, epididymal white adipose tissue; fasn, fatty acid synthase; FATP4, fatty acid transporter
protein 4; HFD, high-fat diet; LAB, α-lactalbumin; Lf, lactoferrin; LFD, low-fat diet; npy, neuropeptide Y; pomc, proopiomelanocortin; sWAT, subcutaneous
white adipose tissue; WPI, whey protein isolate.
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(i.e. L-type amino acid transporter 4; neural amino acid trans-
porter 1 (B0AT1)) into the bloodstream(6).
The complexity of nutrient absorption is further highlighted
by the network of diverse intrinsic and extrinsic factors
regulating this process. With regard to intrinsic factors, it is
notable that deficiency of the anoretic hormone leptin in mice(6)
increases energy ingestion leading to a greater adiposity and
weight gain, coupled with associated hypothalamic–neuro-
peptide changes and chronic intestinal inflammation(7). Simi-
larly, targeted deletion of the gene encoding GLUT2, a key
intestinal glucose transporter, also increases energy intake(8).
Of the extrinsic factors, the gut microbiota plays a key role in
harvesting energy from ingested food and providing it for host
metabolism(9–12). Hence, germ-free mice are protected against
obesity despite consuming more energy content than control
mice, but this phenotype is reverted after faecal microbiota
transplantation from conventionally raised mice(13). Using
gnotobiotic mice fed a high-fat diet (HFD) or low-fat diet (LFD),
respectively, a role has been suggested for Clostridium
ramosum in the upregulation of body fat deposition promoting
factors(14). These data, coupled with the observed impact of gut
microbiota on brain formation, including hypothalamic micro-
structures(15), provide novel avenues for modulating the activity
of the intestine, adipose tissue and hypothalamus, involving
microorganisms.
α-Lactalbumin (LAB) is a globular protein well known as a
source of peptides having beneficial properties such as anti-
oxidant bioactivity and immune modulation ability(16). It con-
stitutes around 25% of the bovine milk whey proteins(16). Whey
can be extracted during the manufacture of cheese and also
comprises other protein types, varying in abundances, includ-
ing β-lactoglobulin (approximately 65%), bovine serum albumin
(BSA, approximately 8%), lactoperoxidase (0·25–0·5%), lacto-
ferrin (Lf, approximately 1%) as well as other minor proteins
such as immunogloblulins (<1%)(17). Recently, whey proteins
have been considered as a potential dietary solution to obesity
in light of the discovery that these proteins, as an isolate (WPI)
or concentrate, acutely increase the production of hormones
that are involved in satiety in both humans and rodents(18,19).
Moreover, intake of whey proteins in humans reduces fat
absorption(20). This effect might be attributed to an altered
composition of the gut microbiota involved in energy harvest,
since other studies have shown that dietary whey proteins can
influence the composition of the gut microbiota(21–24). Indeed,
we showed that WPI reduced the proportion of Firmicutes in
the mouse gut microbiome(22), and this was accompanied by a
reduction in the expression of intestinal nutrient transporters,
specifically glut2 and fatp4. In addition, we showed that WPI
reduced epididymal white adipose tissue (eWAT) weight and
the overall body weight gain. Consistent with changes in the
gut, WPI increased energy intake, which was reflected in the
altered hypothalamic gene expression of neuropeptides,
namely, proopiomelanocortin (pomc), neuropeptide Y (npy)
and ghrelin(22).
While these data suggest a modulatory effect of WPI on the
gut microbiome, hypothalamus and adipose tissue, it was not
clear whether the changes in energy intake were driven directly
from the gut/hypothalamus axis or were secondary to the
changes in adiposity. Indeed, previously it was shown that
specific whey proteins, such as BSA and Lf, influenced in a
different way the body weight, energy intake and plasma leptin
level(25,26).
Given that LAB has been shown to affect the energy balance
but the underlying mechanism is still unclear(27,28), in the cur-
rent study we sought to further investigate the link established
previously between gut–hypothalamic–adipose control of
energy balance using LAB as the main protein source. The
protein was given in a physiological amount (i.e. 20%
energy content) during HFD-induced weight gain phase in the
C57BL/6J strain of mice, which was used as the model for
humans. LAB was introduced early in development (5 weeks of
age), given the WPI specificity to influence weight gain during
this period(29). As the control, we fed mice a LFD or HFD




The in vivo experiments were approved by the University
College Cork Animal Experimentation Ethics Committee (2011/
005) and were licenced under the European Directive 2010/63/
EU. Twenty-four C57BL/6J 3-week-old male-specific pathogen-
free mice were purchased commercially (Harlan) and were
singly housed in each cage with enrichment (Litaspen 8/20 and
alpha-dry Plus bedding; LBS-Biotech, UK) on a 12 h light–12 h
dark cycle with humidity maintained at 45–60% and tempera-
ture between 19 and 22°C. The mice had ad libitum access to
food and water throughout the study unless otherwise stated.
The health of the animals and the environment parameters were
checked and recorded daily. No adverse effects were observed
by the dietary interventions or procedures detailed below. The
mice were provided with a diet containing 10% (low) fat and
20% casein (LFD-CAS; #D12450Bi; Research Diets) (all per-
centage values by energy) during the initial 2-week acclimati-
sation period and then weight-matched mice were switched to
a 45% (high) fat diet containing either 20% casein (HFD-CAS;
#D12451i) or LAB (HFD-LAB; #D13081701i) (n 8 per group).
The controls continued to receive LFD-CAS (n 8). The diets
were OpenSource and were made by Research Diets, with LAB
sourced from Sigma (diets composition details, online Supple-
mentary Table S1). Body weight and food intake were mea-
sured weekly. The latter was converted to gross energy intake
using the dietary energy density of the diets (HFD= 19·79 kJ/g
and LFD= 16·11 kJ/g; Research Diets).
During weeks 8 and 9, mice were placed in TSE PhenoMaster
cages for 3 d to measure metabolic parameters, specifically,
oxygen consumption (ml/h, VO2), carbon dioxide production
(ml/h, VCO2), RER (VCO2/VO2) and locomotor activity (X, Y
and Z planes). The data were collected in the final 24 h of the
housing period as detailed previously(30).
At week 10, mice were fasted for 10–12 h commencing at
22.00 hours in the dark phase, then anaesthetised (100mg/kg
ketamine and 10mg/kg xylazine) and blood samples were
collected. Mice were killed by cervical dislocation and tissues
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were collected and samples were stored at –80°C for sub-
sequent analysis. The length of the small intestine and the
weight of all the tissues were recorded on fresh tissues before
snap freezing them.
DNA sequencing
Faecal samples were collected directly from the colon, homo-
genised and processed using mechanical and chemical lysis.
The 16S rRNA gene (V3–V4 region) was amplified with
universal primers (PCR1 forward and reverse primer as to the
Illumina 16S Metagenomic Sequencing Protocol) that facilitated
sequencing on the Illumina MiSeq platform (2× 250 bp paired-
end reads; V3 sequencing chemistry). The fastq files were
filtered on the basis of quality (removal of low quality nucleo-
tides at the 3′ end) and length (removal of sequences with
<200 nt) with prinseq(31), and paired reads with a minimum
overlap of 20 bp were joined using Fastq-join(32).
Sequences were clustered (97% identity) to obtain operative
taxonomic units (OTU) using closed-reference usearch version
7.0 algorithm(33) and chimeric OTU were removed using the
gold database. The taxonomic assignment of OTU was obtained
using the ribosomal database project(34). α- and β-diversities
were determined using QIIME(35), and additional analyses were
performed with the R package phyloseq(36).
To identify chow-associated microbes, total DNA was
extracted from approximately 10 g of chow containing 20% fat
and 20% casein (LFD-CAS; #D17052702; Research Diets), and
approximately 10 g of chow containing 40% fat and 20% casein
(HFD-CAS; #D17052705; Research Diets) using the Gene All
Extragene SoilSV kit (GeneAll). The Qubit high-sensitivity DNA
assay (Bio-Sciences Limited) was used for accurate quantifica-
tion of the total DNA. Whole-metagenome shotgun library
preparation was performed following the Nextera XT DNA
library preparation guide from Illumina(37) and sequencing was
performed using the Illumina NextSeq 500 with a v2 NextSeq
500/550 high-output reagent kit (300 cycles).
The raw shotgun metagenomic sequences were filtered on
the basis of quality (removal of low-quality nucleotides at the 3′
end and application of sliding window trimming, cutting once
the average quality within the window falls below a threshold
quality of 20 bp) and length (removal of sequences of <200 nt)
with prinseq(31). The filtered sequences were then converted to
bam files using SAMtools(38), and duplicate reads were subse-
quently removed using Picard tools (https://github.com/
broadinstitute/picard). The quality of the sequences was tested
using SAMtools in combination with Picard Tools, removing the
low-quality sequences. Taxonimic analysis was performed
using Kaiju(39).
Gene expression
The small intestine samples, stored at –80°C, were initially
immersed in a RNAlater-Ice frozen tissue transition solution and
stored at –20°C, according to the instructions of the manu-
facturer (Ambion). This step allows untangling of the intestine
while preserving the integrity of the RNA, so that tissue samples,
corresponding to the ileum (1 cm from the distal end of the
small intestine) and jejunum (the central part of the small
intestine), could be cut.
Total RNA was extracted from the intestinal samples and
hypothalamic blocks using RNeasy Minikit and QIAshredder
columns (Qiagen), and from eWAT and subcutaneous white
adipose tissue (sWAT) using QIAzol Lysis Reagent (Qiagen).
The extracted RNA was treated with DNase (Qiagen). Com-
plementary DNA was synthetised from 600 ng total RNA using
Superscript™ II reverse transcriptase kit (Life Technologies) and
subjected to real-time PCR (Roche) using SYBR Green Select
Master Mix (Roche) as detailed before(40). The gene expression
was calculated using 2ΔΔCp and normalised against the refer-
ence gene β-actin (intestine and adipose tissue) and ywhaz (i.e.
tyrosine 3-monoxygenase/tryptophan 5-monoxygenase activa-
tion protein, zeta polypeptide; hypothalamus). The sequence of
the primers can be found elsewhere(25,30,40).
Plasma leptin, glucose and TAG levels
Plasma leptin and glucose levels were determined using Mouse
Leptin ELISA kit (Crystal Chem) and Mouse Glucose Assay
(Crystal Chem), respectively. TAG level in the plasma was
measured using Triglyceride Quantification Assay kit (Abcam).
Statistical analysis
For power calculation, the CV was measured using data (body
weight gain) from a previous study(40) and determined to be
8·8%. For a power of 80% and a significance level of 5%, this
allows detection of a difference of 14% with a sample size of
eight mice per treatment. Body weight and energy intake dif-
ferences over 10 weeks were analysed by a two-way repeated-
measures ANOVA with Bonferroni’s post hoc pairwise com-
parisons. Statistical analysis of gene expression, cumulative
energy intake, intestine weight/intestine length, plasma leptin
and TAG data were performed using one-way ANOVA followed
by pairwise comparison using Bonferroni’s post hoc test. Non-
parametric data were compared by Kruskal–Wallis ANOVA
followed by the Mann–Whitney U test. Data were expressed as
means with their standard errors and significance was set at
P< 0·05 using SPSS software version 24 (IBM Corp.). VO2 and
heat production were analysed by ANCOVA (SAS software
version 9.3), with total body weight being used as the covariant.
Gut microbiota data were statistically analysed by Adonis and
Anosim for β-diversity analysis. ANOVA was used to calculate
significance for α-diversity-related analyses (statistical sig-
nificance established at P< 0·05). Statistical differences across
multiple samples were determined by Kruskal–Wallis, and false
discovery rate (q value) control based on the Benjamini–
Hochberg procedure was used to correct for multiple testing
with the R statistical package (https://www.r-project.org/). Test
for association across all groups of samples was performed
through correlation analysis. This was based on Spearman’s
rank correlation test by the R function of cor.test, which aimed
to examine similar expression association profiles between
groups of samples (https://www.r-project.org/package=corr
plot) and adjustment of the P value by the Benjamini–Hochberg
method. Statistical significance was established at P< 0·05 (*),
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with other ranges, i.e. P< 0·01 (**) and P< 0·001 (***), also
being noted.
Results
α-Lactalbumin increased cumulative energy intake but not
weight gain
Mice fed HFD-LAB and HFD-CAS had similar body trajectories
(Fig. 1(a)) but differed from the LFD-CAS group in the time
taken to increase weight. Notably, the HFD-CAS group had a
significantly higher weight than LFD-CAS by week 3 (P= 0·033),
while the weight of the HFD-LAB group did not significantly
exceed that of the LFD-CAS group until week 6 (P= 0·045)
(F8,160= 440·2, P< 0·001 for the effect of the time, F2,20= 5·5,
P< 0·05 for the effect of the diet, F16,160= 11·6, P< 0·001 for the
effect of the time× diet interaction) (Fig. 1(a)). Despite having
similar body weight trajectories, the energy intake of HFD-LAB
showed a trend towards an increase at week 2 (P= 0·053) (413
(SEM 9) kJ in HFD-LAB, 383 (SEM 8) kJ in HFD-CAS and 293
(SEM 8) kJ in LFD-CAS) and it was higher in HFD-LAB compared
with HFD-CAS at week 4 (P= 0·037) (F7,140= 7·2, P< 0·001 for
the effect of the time, F2,20= 81·7, P< 0·001 for the effect of the
diet, F14,140= 1·3, P> 0·05 for the effect of the time× diet
interaction) (Fig. 1(b)). The cumulative energy intake of HFD-
LAB was significantly increased by week 10 relative to HFD-
CAS (P= 0·043) (Fig. 1(c)). The difference in energy intake was
reflected in the hypothalamic expression of neuropeptides.
Notably, at week 10, the expression of the anorexigenic neu-
ropeptide pomc was reduced relative to the LFD-CAS control
(P= 0·043 compared with HFD-CAS and P= 0·001 compared
with HFD-LAB), without showing significant difference
between the two HFD groups (Fig. 1(d)). While the gene
expression for the orexigenic neuropeptides ghrelin and npy
remained unchanged, the gene expression of growth hormone
secretagogue receptor (ghsr) was reduced in both HFD groups
compared with LFD-CAS (P= 0·012 relative to HFD-CAS and
P= 0·001 relative to HFD-LAB) (Fig. 1(d)). Similar to pomc
expression, the expression of ghsr between HFD-CAS and HFD-
LAB groups did not change. There was no effect due to diet on
the expression of the fatty acid synthase (fasn). The mismatch
between energy intake and weight gain was unrelated to
energy expenditure as both HFD-CAS and HFD-LAB groups
had similar 24 h VO2 levels (97 (SEM 3) in HFD-LAB, 95 (SEM 3) in
HFD-CAS and 101 (SEM 3) in LFD-CAS; all values in ml/h) and
heat production (2·1 (SEM 0·05) in HFD-LAB, 2·0 (SEM 0·05) in
HFD-CAS and 2·2 (SEM 0·06) in LFD-CAS; all values in kJ/h),
where both parameters were measured during weeks 8 and 9.
There were no differences between groups in terms of 24 h
locomotor activity (303 (SEM 28) in HFD-LAB, 293 (SEM 29) in
HFD-CAS and 365 (SEM 37) in LFD-CAS). While the HFD-CAS
and the HFD-LAB groups had similar RER, the corresponding
values were lower compared with LFD-CAS (both with
P< 0·001), consistent with increased fat consumption by former
groups (0·816 (SEM 0·014) in HFD-LAB and 0·809 (SEM 0·014) in
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Fig. 1. ɑ-Lactalbumin (LAB) affects cumulative energy intake without affecting body weight gain. Impact of a high-fat diet containing casein (HFD-CAS), high-fat diet
containing LAB (HFD-LAB) and a low-fat diet containing casein (LFD-CAS) on body weight (a) and energy intake (b) trajectories during a 10-week feeding experiment.
Also shown is the cumulative energy intake (c) after 10 weeks. In the hypothalamus was detected the level of expression of some genes involved in energy balance
control (d) after 10 weeks of HFD-CAS or HFD-LAB intake relative to the control group LFD-CAS. pomc, Proopiomelanocortin; npy, neuropeptide Y; ghsr, growth
hormone secretagogue receptor; fasn, fatty acid synthase. Statistical analysis: groups showing * are significant (* P< 0·05, ** P< 0·01, *** P< 0·001). Cumulative
energy intake, one-way ANOVA: F(2,22)= 81·7 (P< 0·001 followed by Bonferroni's post hoc test). Hypothalamic gene expression, one-way ANOVA: pomc F(2,22)= 9·2
(P< 0·01); npy F(2,22)= 2·8 (P= 0·079); ghsR F(2,22)= 9·8 (P< 0·01); all followed by Bonferroni's post hoc test except npy. (a, b) , LFD-CAS; , HFD-CAS;
, HFD-LAB. (c, d) , LFD-CAS; , HFD-CAS; , HFD-LAB.
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α-Lactalbumin decreases the intestinal expression of
glucose and fatty acid transporters
To find an explanation for the apparent energy loss in the HFD-
LAB group, the impact on gastro-intestinal size and related gene
expression of several nutrient transporters were measured. The
intestinal length was unaffected by the diet (33·2 (SEM 0·61) cm
in HFD-LAB, 32·4 (SEM 0·74) cm in HFD-CAS and 32·9 (SEM
0·38) cm in LFD-CAS). While the intestinal weight expressed
relative to the length and body weight was similar between
HFD-CAS and HFD-LAB groups, this was significantly lower
compared with LFD-CAS controls (P= 0·039 relative to HFD-
CAS and P= 0·019 relative to HFD-LAB) (Fig. 2(a)). The data
from ANCOVA showed that there was no significant effect of
diet on intestinal weight/length when the body weight was
used as a covariant (0·024 (SEM 0·001) g in HFD-LAB, 0·025 (SEM
0·001) g in HFD-CAS and 0·026 (SEM 0·001) g in LFD-CAS).
In the ileum, we observed a significant decrease in the
expression of the sglt1 in both high-fat groups compared with
the LFD-CAS (P= 0·026 relative to HFD-CAS and P= 0·029
relative to HFD-LAB), but glut2 gene expression was specifi-
cally reduced in the HFD-LAB compared with LFD-CAS
(P= 0·01), and it showed a trend towards a decrease, at the
significance threshold, compared with HFD-CAS (P= 0·053)
(Fig. 2(b)). While fatp4 gene expression was unaffected in the
ileum, the cd36 (an integral membrane protein responsible for
importing fatty acids into the cell) was reduced in the HFD-LAB
compared with the LFD-CAS (P= 0·001) and HFD-CAS
(P< 0·001) (Fig. 2(b)). The expression of genes encoding the
L-amino acid transporter, lat4, and the neutral amino acid
transporter slc6a19 was not significantly affected (Fig. 2(b)).
The same gene expression was measured in the jejunum.
Similar to the ileum data, cd36 gene expression in the jejunum
was reduced in the HFD-LAB group compared with the other
two groups (P= 0·001 relative to LFD-CAS and P< 0·001 relative
to HFD-CAS), whereas glut2 expression did not change across
the groups (Fig. 2(c)). In addition, in the jejunum, the level of
expression of fatp4 was significantly higher in the HFD-LAB
group compared with the LFD-CAS control group (P< 0·001),
and the expression of lat4 showed a trend towards an increase
in the HFD-LAB-fed mice relative to HFD-CAS-fed mice
(P= 0·061) (Fig. 2(c)).
In light of the results obtained for glut2 and cd36 gene
expression, we measured the levels of glucose and TAG in the
plasma. We observed that the glucose in the plasma of HFD-
LAB-fed mice (3·11 (SEM 0·23) mg/ml) was not significantly dif-
ferent from HFD-CAS (2·93 (SEM 0·08) mg/ml) but was lower
compared with LFD-CAS-fed mice (3·64 (SEM 0·08) mg/ml
P= 0·018). The level of TAG in the HFD-LAB (0·37 (SEM 0·04)
mg/ml), HFD-CAS (0·35 (SEM 0·06) mg/ml) and LFD-CAS (0·36
(SEM 0·05) mg/ml) groups was not significantly different.
α-Lactalbumin does not affect leptin gene expression and
plasma hormone availability
Several tissues were harvested from the mice and their weights
were recorded (Fig. 3(a)). The weights of both the sWAT and
the eWAT were greater in both the HFD groups compared with
the LFD-CAS control group (sWAT: P= 0·002 relative to HFD-





































































































Fig. 2. α-Lactalbumin (LAB) influences the expression of nutrient transporters
within the small intestine. (a) Effect of LAB on intestine weight normalised by
intestine length per 100 g of body weight. Level of gene expression in the ileum
(b) and jejunum (c) after 10 weeks of intake of high-fat diet containing casein
(HFD-CAS; ) or high-fat diet containing LAB (HFD-LAB; ) relative to the
control low-fat diet containing casein (LFD-CAS; ). sglt1, Sodium-glucose
transporter 1; glut2, glucose transporter 2; cd36, cluster of differentiation 36;
Slca19, methionine transporter; fatp4, fatty acid transporter 4; lat4, L type amino
acid transporter 2. Statistical analysis: groups showing * are significant
(* P<0·05, ** P<0·01, *** P<0·001). Intestine weight/intestine length, one-
way ANOVA: F(2,20)=5·5 (P<0·05) followed by Bonferroni's post hoc test.
Ileum gene expression: Kruskal–Wallis test for sglt1 (P=0·035) and cd36
(P<0·001). Mann–Whitney U test for sglt1: 1 v. 2 U(15)=9 (P=0·029); 1 v. 3
U(14)=7 (P=0·026). Mann–Whitney U test for cd36: 1 v. 3 U(14)=0 (P=0·001); 2
v. 3 U(15)=0 (P<0·001). One-way ANOVA: glut2 F(2,19)=6·4 (P<0·01). Jejunum
gene expression: Kruskal–Wallis test for cd36 (P=0·001) and fatp4 (P=0·016).
Mann–Whitney U test for cd36: 1 v. 3 U(14)=0 (P=0·001); 2 v. 3 U(15)=0
(P<0·001). Mann–Whitney U test for fatp4: 1 v. 3 U(15)=0 (P<0·001). One-way
ANOVA: lat4 F(2,20)=3·6 (P<0·05) followed by Bonferroni's post hoc test.
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relative to HFD-CAS and P< 0·001 relative to HFD-LAB), but no
differences were observed in the adipose tissue weights
between HFD-CAS and HFD-LAB (Fig. 3(a)). Next, the
expression of several genes involved in the catabolism and
anabolism of fatty acids in the eWAT and sWAT was measured.
In the present study, the expression in the eWAT of genes
involved in fatty acid catabolism (carnitine palmoitoyltransfer-
ase I, cpt1; uncoupling protein, ucp; hormone-sensitive lipase,
hsl; β-3 adrenergic receptor β-3ar) and anabolism (acetyl CoA
carboxylase 1, acc1; fasn; lipoprotein lipase, lpl) between
HFD-LAB- and HFD-CAS-fed animals did not differ (Fig. 3(b)
and (c)). There was also no change in the expression of genes
involved in fatty acid transport, such as cd36, fatp1 and glut4
(Fig. 3(c)). However, consistent with the increased adiposity of
the high-fat-fed groups, acc1 gene expression was down-
regulated in HFD-CAS (P= 0·008) and HFD-LAB (P= 0·002)
compared with LFD-CAS (Fig. 3(c)). In addition, the inflam-
matory marker, cluster of differentiation 68 (cd68) expression
showed a trend towards an increase in the HFD-CAS group
compared with the LFD-CAS (P= 0·057); but for the HFD-LAB
group, the increase was not significant relative to LFD-CAS (Fig.
3(c)). The unchanged adipose tissue weights, coupled with
gene expression data in the eWAT, suggest an alternative


















































































































































Fig. 3. Effect of ɑ-lactalbumin (LAB) on tissue weights and on the expression of genes involved in the catabolism and anabolism of adipose tissue. (a) Tissue weights
normalised by 100 g of body weight. Expression of catabolic (b) and anabolic (c) genes in the epididymal white adipose tissue (eWAT) was investigated after 10 weeks
of intake of high-fat diet containing casein (HFD-CAS; ) or high-fat diet containing LAB (HFD-LAB; ) relative to the control low-fat diet containing casein (LFD-CAS;
□). cpt1a and cpt1b, Carnitine palmitoyltransferase I, hsl, hormone-sensitive lipase; ucp2 and ucp3, uncoupling protein; β3-AR, β-3 adrenergic receptor; acc1, acetyl-
CoA carboxylase; ob, leptin gene; cd68, cluster of differentiation 68; fasn, fatty acid synthase, fatp1, fatty acid transporter 1; glut4, glucose transporter 4; lpl, lipoprotein
lipase; cd36, cluster of differentiation 36. Again after 10 weeks, the level of serum leptin (d) was measured in the three groups. Expression of the genes ob, fasn and
glut4 (e) in the subcutaneous white adipose tissue (sWAT). Statistical analysis: groups showing * are significant (* P< 0·05, ** P< 0·01, *** P< 0·001). Tissue weights:
one-way ANOVA sWAT F(2,22)= 8·3 (P<0·01); stomach F(2,22)= 3·4 (P= 0·051); intestine F(2,20)= 4 (P< 0·05); eWAT F(2,21)= 12·7 (P< 0·001); all followed by
Bonferroni's post hoc test. eWAT gene expression (anabolism): Kruskal–Wallis test for acc (P= 0·007). Mann–Whitney U test for acc: 1 v. 2 U(15)= 4 (P=0·008); 2 v. 3
U(15)= 1 (P= 0·002). One-way ANOVA ob F(2,21)= 12·6 (P< 0·001); cd68 F(2,21)= 3·5 (P< 0·05); both followed by Bonferroni's post hoc test. Plasma leptin: one-way
ANOVA F(2,22)= 3·3 (P= 0·056). sWAT gene expression: one-way ANOVA ob F(2,21)= 8·2 (P<0·01) followed by Bonferroni's post hoc test. Kruskal–Wallis test for fasn
(P= 0·001) and glut4 (P= 0·032). Mann–Whitney U test for fasn: 1 v. 2 U(15)= 1 (P=0·001); 1 v. 3 U(14)= 0 (P= 0·001). Mann–Whitney U test for glut4: 1 v. 2 U(15)= 8
(P= 0·021); 1 v. 3 U(13)= 6 (P= 0·035).
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measured leptin (ob) gene expression in the eWAT to assess
whether there is a specific effect of LAB in leptin regulation,
similar to that attributed to the whey protein Lf(26).
Consistent with the gain in body weight and adipose
tissue weight, the expression of the ob gene in the HFD-CAS
group increased compared with the control LFD-CAS
(P< 0·001); and in the HFD-LAB group, it showed a trend
towards an increase relative to the LFD control (P= 0·059),
without showing any differences between the two HFD groups
(P= 0·08) (Fig. 3(c)).
Similarly, no differences in ob expression were detected in
the sWAT between the HFD groups (Fig. 3(e)), and the
expression of fasn and glut4 genes were decreased com-
pared with the LFD-CAS group (fasn: P= 0·001 relative to
HFD-CAS and P= 0·001 relative to HFD-LAB; glut4: P= 0·021
relative to HFD-CAS and P= 0·035 relative to HFD-LAB),
with no difference between HFD-CAS and HFD-LAB groups
(Fig. 3(e)).
The ob gene expression in eWAT and sWAT was reflected in
the plasma availability of leptin, as the presence of LAB in the
HFD did not influence the plasma hormone level, relative to
HFD-CAS (Fig. 3(d)).
β-Diversity and gut bacterial composition differs due to
α-lactalbumin intake
After quality filtration and length trimming, an average of
182 494 high-quality 16S rRNA sequences per sample (i.e. faecal
pellets collected from the colon) were obtained across two
groups, that is, HFD-CAS (n 8) and HFD-LAB (n 8). Analysis of
these data revealed that, while α-diversity did not differ sig-
nificantly across groups, a significant difference in β-diversity
(P= 0·002) between the microbiota of the HFD-CAS and HFD-
LAB animals was apparent, as represented by distinct clustering
upon principal coordinate analysis of all 16S rRNA reads
(clustered at 97% similarity) (Fig. 4(a)).
Differences in β-diversity were reflected by taxonomic dif-
ferences between the HFD-CAS and HFD-LAB groups. At the
phylum level, a lower Firmicutes/Bacteroidetes (ratio F/B) was
apparent in the HFD-CAS samples (ratio F/B= 1·23) relative to
the HFD-LAB equivalents (ratio F/B= 1·42), though significance
was not achieved (Fig. 4(b)). At the family level, two families
differed significantly in a diet-associated manner, namely, Lac-
tobacillaceae (higher levels in HFD-LAB samples) and Strepto-
coccaceae (higher proportions in HFD-CAS samples) (Table 1).
Fig. 4. Impact of ɑ-lactalbumin (LAB) on the composition of the gut microbiota. (a) β-Diversity of the two groups (high-fat diet containing casein (HFD-CAS), red; high-
fat diet containing LAB (HFD-LAB), light blue) calculated using principal coordinate analysis. (b) Bar chart representing the phylum-level proportions in faecal samples
of mice fed with HFD-CAS and HFD-LAB using the Kruskal–Wallis method, showing Firmicutes (light purple), Bacteroidetes (blue), Proteobacteria (brown),
Deferribacteres (dark purple) and other taxa (green). (c) Heatmap illustrating Spearman's rank correlations between the abundance of family- and genus-level gut
microbes and cd36 expression, energy intake and glucose transporter 2 (glut2) expression and in both the HFD-CAS and HFD-LAB groups. The P value adjustment
was done using the Benjamini–Hochberg method. Groups showing * are significant (* P< 0·05, ** P< 0·01, *** P< 0·001; for statistical analysis, see the Methods
section).
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At the genus level, statistically significant differences were
apparent in the abundance of Parabacteroides, Bifidobacterium,
Parvibacter and Lactobacillus, all of which were present in
higher proportions in the HFD-LAB sample groups as well as
Lactococcus, Roseburia (P= 0·021), Phascolarctobacterium
(P= 0·018) and Turicibacter, present in higher proportions in the
HFD-CAS group (Table 1), were noted.
To assess the possibility that the presence of particular taxa
within the chow containing CAS could be responsible for the
associated increased proportion of Streptococcaeae in the gut, the
microbiota of the CAS-containing chow was analysed. This
revealed that the family Streptococcaceae (99·6 and 99·8% in LFD-
CAS and HFD-CAS chow, respectively) and the associated genus,
Lactococcus (99·6 and 99·8% in LFD-CAS and HFD-CAS chow,
respectively), were dominant (online supplementary Table S2).
Correlation and independent analyses of the associated pro-
files were conducted between cd36 and glut2 expression
levels, as well as energy intake, against bacterial composition at
the genus level. Dairy taxa potentially sourced from the food
substrate were not considered. After adjustment for multiple
testing (Benjamini–Hochberg-corrected), it was noted that
energy intake positively correlated within the group of HFD-
CAS samples with Parabacteroides. Within the HFD-LAB group,
Parabacteroides negatively correlated with cd36 expression.
Glut2 expression was positively correlated with Para-
bacteroides in HFD-LAB samples (Fig. 4(c)).
Discussion
In this study, we investigated the effects of a specific dietary
whey protein (LAB) on intestinal–adipose–hypothalamic con-
trol of energy balance. We show that supplementation of LAB in
an HFD reduced cd36 and glut2 gene expression in the intes-
tine and was associated with changes in the composition of the
gut microbiota. These changes were accompanied by increased
cumulative energy ingestion. This, coupled with the fact that
targeted deletion of the glut2 gene increases energy intake(8),
suggests a potential link between gut microbiota, intestinal
nutrient transporters and energy intake in response to LAB
supplementation. These effects were unrelated to adiposity, as
HFD-LAB-fed mice had similar weight gain, adipose tissue
weight (both eWAT and sWAT) and plasma TAG.
Previous studies have shown that diets rich in whey proteins
cause short-term satiety effects in mice and in humans(41–43).
Long-term effects on energy balance, however, do not involve
the production of satiety hormones(19). On a background of
HFD intake, which has been shown to reduce the brain sensi-
tivity to satiety hormones(44), the increased energy intake in
mice fed with HFD-CAS compared with LFD and even higher
(cumulative) energy intake in HFD-LAB is likely to involve
another mechanism of regulation within the adipose tissue–gut–
brain connection.
Hypothalamic–neuropeptide expression provided an insight
into the regulatory effect of LAB on energy intake. Notably, the
expression of the anorexigenic neuropeptide pomc gene expres-
sion was significantly lower in the HFD-CAS group in line with the
higher energy intake compared with LFD-CAS, similar to that
shown in previous studies(26,30). In the HFD-LAB group, while
pomc expression remained low, the expression of the orexigenic
neuropeptide, npy, did not change across the groups. In contrast,
effects on energy intake and on hypothalamic pomc and npy
expression were previously found in mice fed with WPI compared
with casein in an LFD(22). In addition, neither the expression of
npy nor the cumulative energy intake changed in mice fed a HFD-
containing Lf compared with casein(26). These data suggest that the
whey protein LAB have bioactivity that influences energy intake
and that is not mediated by the modulation of hypothalamic
neuropeptide genes investigated in this study.
In the present study, while the HFD-CAS group increased
weight rapidly, reaching a significant increase relative to LFD
values by week 3, it was a further 3 weeks before the mice fed
HFD-LAB diet significantly increased body weight relative to
LFD-fed animals. The finding that the higher cumulative energy
intake was not reflected in the increased body weight in the
HFD-LAB group suggests a mechanism must exist to explain the
missing energy from the supply. This is consistent with a rat
study, which showed that HFD intake with LAB did not change
energy intake but decreased adiposity(27). The difference in
energy intake between this study and our present study could be
related to the fact that the rat study included both egg albumin
and LAB as the protein sources in the same diet, whereas we
used LAB as the only protein source. This apparent energy loss
could be related to lipid oxidation, as a recent study showed that
pre-exercise LAB-enriched whey protein meal preserved lipid
oxidation alongside rapid delivery of amino acids to tissues for
use during exercise, decreasing the adiposity in rats(45). How-
ever, we did not observe this effect in the sedentary mice used in
our present study, as RER was similar between HFD-LAB- and
HFD-CAS-fed mice, and adipose-specific gene expression linked
to lipid catabolism also did not change. This, coupled with the
similar sWAT and eWAT weights between HFD-LAB and HFD-
CAS groups, suggests that the energy loss in the sedentary mice
fed LAB occurs through another mechanism.
It has been shown previously that WPI reduces fat absorption
in humans and mice(29,46,47), and we showed that this effect
could be related to decreased ileal fatp4 gene expression(22). In
addition, we also showed a time course reduction of glut2 gene
expression in the same region with 17 weeks of WPI intake, and
Table 1. Relative abundance (%) of genera and families in which their
abundance is significantly higher either in the high-fat diet (HFD)-casein
(CAS) group or in the HFD-α-lactalbumin (LAB) group*
HFD-LAB v. HFD-CAS Relative abundance
Family
Streptococcaceae P=0·029 ↑ HFD-CAS 0·082895775
Lactobacillaceae P=0·015 ↑ HFD-LAB 1·18133309
Genus
Lactococcus P=0·001 ↑ HFD-CAS 0·077810661
Turicibacter P=0·024 ↑ HFD-CAS 0·301261529
Streptococcus P=0·001 ↑ HFD-LAB 0·148479572
Parvibacter P=0·039 ↑ HFD-LAB 0·012092907
Lactobacillus P=0·011 ↑ HFD-LAB 1·180503082
Parabacteroides P=0·026 ↑ HFD-LAB 0·045986668
Bifidobacterium P=0·050 ↑ HFD-LAB 0·159330093
* Statistical differences across multiple samples were estimated by the bioinformatics
methods ‘false discovery rate’ control based on the Benjamini–Hochberg
procedure.
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this effect on intestinal gene expression was independent of
sucrose content in the diet(22). In the present study, by feeding a
constituent protein of WPI, that is, LAB, to mice for a shorter time
period (10 weeks) and by analysing their intestinal gene
expression, we now observed a reduction in the expression of
sglt in both HFD groups relative to LFD groups. This can be a
reflection of higher carbohydrate content in the LFD compared
with the two HFD (online Supplementary Table S1). In addition,
we show a reduction in glut2 expression in the ileum exposed to
HFD, specifically with LAB. The similar effects of LAB and WPI
on intestinal glut2 expression in the ileum suggest that LAB may
contribute to the bioactivity in WPI influencing glut2 expression;
and this bioactivity, whatever it may be, appears to be effective
independent of sucrose or fat content in the diet(22). It was shown
that the recruitment of apical GLUT2 in the small intestine is
detrimental for health, that is, it leads to an excess of glucose
uptake with increased obesity and type 2 diabetes risk(48). Our
study suggests a potential effect of a diet enriched in LAB in the
control of intestinal GLUT-related transcripts that could influence
glucose absorption. In another in vitro study, using human
intestinal Caco-2 cells, it was shown that polyphenols can also
lead to a decrease in the abundance of apical GLUT2(49).
In the present study, we observed also a reduction in cd36
gene expression within both ileum and jejunum. Thus, in combi-
nation, these data further support the hypothesis that whey protein
LAB seems to affect different components of the mechanism
involved in the absorption of glucose and fatty acids within the
small intestine, at least at the gene expression level. This would
explain, at least in part, the loss of energy that occurs in mice fed
LAB. Further analysis aimed to look at the protein level and energy
content in the faeces need to be done to confirm this hypothesis.
Notably, differences in the level of cd36 and glut2 in the jejunum
during LAB intake are in agreement with the fact that the modality
and the degree of absorption can change along the intestinal tract.
This is due to a different density of nutrient transporters across the
three major regions of the small intestine(50). Based on the effect of
LAB in an HFD on the expression of nutrient transporters in the
intestinal epithelium and associated energy loss, we speculate that
mice compensate by increasing energy intake. In fact, in this study
we observed that the levels of glucose and TAG in the plasma did
not show significant changes between HFD groups.
Furthermore, the HFD groups consumed more energy than
LFD. Since there were no differences in the energy expenditure,
the energy surplus has been stored in the adipose tissue. Thus,
the lower expression of acc and fasn in the adipose tissue,
presumably reflects the reduced necessity to produce fat
endogenously when there is an external supply of excess
energy. A similar reduction in fasn gene expression has been
noted in a previous study(21). On the contrary, other studies
show that HFD intake increases fasn and acc in the adipose
tissue(51–53). The reasons for these discrepancies are unclear,
but we speculate that contributing factors can include different
genetic background, age, diet (composition and duration) and
different housing environment.
Leptin, a hormone encoded by the ob gene, controls food
intake and body weight through an interaction with specific
receptors within the hypothalamus(54). In obese humans and in
mice fed an obesogenic diet, the adipose tissue mass increases,
enhancing significantly the level of serum leptin and leading to
metabolic dysfunctions(55). In addition to the effect on intestinal
nutrient transporters and energy intake, WPI in an LFD also
reduced eWAT weight and plasma leptin, raising the possibility
that the reduced adipose tissue and associated signals, including
reduced leptin, could have stimulated the energy intake in mice.
However, feeding mice with an HFD containing 20% of WPI for
8 weeks did not have an effect on plasma leptin levels, compared
with mice fed an HFD containing CAS(30). On the contrary, HFD
containing Lf significantly reduced plasma leptin levels compared
with the HFD-CAS controls(26). This is another demonstration of
the distinct bioactivities that WPI-associated whey proteins can
have. In this study, mice fed an HFD containing LAB as the sole
protein source showed no significant decrease in plasma leptin,
which reflected no change in eWAT and sWAT ob gene expres-
sion in the HFD-LAB group, compared to the HFD-CAS group.
We also demonstrated that an HFD containing LAB has a
strong influence on the composition of the gut microbiota.
β-Diversity data highlighted differences in the clustering of
samples from the HFD-LAB group compared with the HFD-CAS
group. Corresponding taxonomic analyses were also completed.
In particular, we observed a significantly higher proportion of
Parabacteroides in the HFD-LAB group, which is notable in that
this genus showed a significantly positive correlation with the
expression of nutrient transporters. Notably other studies have
suggested that Parabacteroides protects the gut from inflamma-
tion and there have been reports of the apparent absence of this
genus in the digestive tract of people with inflammatory bowel
diseases(56,57). We also observed that the genera Bifidobacterium
and Lactobacillus are significantly more abundant in the HFD-
LAB group. In several human studies, an association was noted
between lower levels of Bifidobacterium and obesity(58–60). In
addition, higher levels of Bifidobacterium have been linked with
an increase in SCFA production, an improvement in gut mucosal
barrier and lower intestinal lipopolysaccharide levels(60,61). Fur-
thermore, specific strains of Bifidobacterium and Lactobacillus
spp. have been shown to exhibit anti-obesity effects(62). It is
worth highlighting the importance of species and strain-level
differences as, for example, human and animal studies have
highlighted an association between different Lactobacillus spe-
cies with weight gain or weight protection(63,64). For this reason,
more accurate in-depth metagenomic analyses, such as shotgun
analysis, should be considered in the future to investigate the
Lactobacillus species that populate the gut of HFD-LAB-fed mice.
A number of bacterial taxa typically associated with dairy
products were also found to be altered in the gut. A recent
human feeding study demonstrated that many bacteriophages
and Streptococcus and Lactococcus genera, that were sig-
nificantly altered in individuals whose diet was supplemented
with whey proteins, were present in high proportions within the
whey protein supplement(65) and thus presumably originated
from the food source. The family Streptococcaceae and the
associated genus, Lactococcus, are significantly more abundant
in the HFD-CAS group compared with the HFD-LAB group.
This is consistent with our previous study that showed that
Streptococcaceae proportion increased significantly in the CAS-
fed mice compared with the WPI-fed mice(22). However, this
phenomenon is likely a reflection of the high proportion of
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Streptococcaceae and Lactococcus reads detected after analysis
of both LFD-CAS and HFD-CAS chows.
The changes in the gut microbiota in the presence of LAB,
coupled with the reduced intestinal expression of genes for
nutrient transporters, support and provide a potential scenario for
the energy mismatch in the HFD-LAB group compared with the
control group. However, the specific mechanism that connects
these changes in intestinal transporters’ gene expression, gut
microbiota and energy intake in the presence of LAB remains to
be elucidated. Further studies are needed to assess whether these
effects are seen with different genetic background, sex, housing
environment (group v. single housing) and dietary fat content
and duration. In conclusion, this present study has demonstrated
for the first time, how an HFD containing a specific whey protein,
that is, LAB, specifically affects the metabolism, microbiota and
nutrient absorption regulation, without preventing weight gain
and adipose tissue mass accumulation in mice.
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